TY - JOUR
T1 - Patients with nonalcoholic steatohepatitis experience severe impairment of health-related quality of life
AU - Younossi, Zobair M.
AU - Stepanova, Maria
AU - Lawitz, Eric J.
AU - Reddy, K. Rajender
AU - Wong, Vincent Wai Sun
AU - Mangia, Alessandra
AU - Muir, Andrew J.
AU - Jacobson, Ira
AU - Djedjos, C. Stephen
AU - Gaggar, Anuj
AU - Myers, Robert P.
AU - Younossi, Issah
AU - Nader, Fatema
AU - Racila, Andrei
N1 - Funding Information:
Guarantor of the article: Zobair M. Younossi, MD, MPH. Specific author contributions: Z.M.Y. obtained funding, designed and supervised the study, and revised the manuscript; M.S. ran data analysis and prepared the first draft; E.J.L., K.R.R., V.W.S.W., A.M., A.J.M., I.J., C.S.D., A.G., R.P.M., I.Y., F.N., and A.R. participated in the study and revised the manuscript. Financial support: This project was partially supported by Gilead Sciences. Potential competing interests: Z.M.Y. has received research funds or served as a consultant to Gilead Sciences, Intercept, Novo Nordisk, Bristol-Myers Squibb, Abbvie, Terns, and Viking; I.M.J. has received research funds or served as a consultant to Abbvie, Assembly, Bristol-Myers Squibb, Gilead Sciences, Intercept, Jans-sen, Merck, and Novo Nordisk; A.G. and R.P.M. are employees of Gilead Sciences; all other authors have no conflict of interest to disclose.
Publisher Copyright:
© 2017 Wolters Kluwer Health. All rights reserved.
PY - 2019/10
Y1 - 2019/10
N2 - INTRODUCTION: Although there is substantial evidence suggesting poor health-related quality of life (HRQL) in patients with chronic hepatitis C (CHC), similar data in nonalcoholic steatohepatitis (NASH) have not been fully assessed. The aim is to compare HRQL scores in patients with CHC to those with NASH. METHODS: Matched patients with advanced fibrosis (bridging fibrosis and compensated cirrhosis) due to CHC and NASH completed Short Form-36 (SF-36) questionnaire, Chronic Liver Disease Questionnaire (CLDQ), and Work Productivity and Activity Instrument questionnaire. RESULTS: We included 1,338 patients with NASH with advanced fibrosis (mean age 57.2 years, 47% men, 55% cirrhosis) and 1,338 matched patients with CHC. Patients with CHC and NASH had similar rates of employment and psychiatric disorders (P > 0.05). As expected, patients with NASH had higher body mass index (mean 33.7 vs 27.6) and more type 2 diabetes (74% vs 16%) (all P < 0.01). Patients with NASH had significantly lower HRQL scores related to physical health: Physical Functioning, Bodily Pain, General Health, Vitality, Physical Summary of SF-36, and Fatigue of CLDQ (P < 0.02). By contrast, patients with CHC had a lower Mental Health score of SF-36 and Emotional score of CLDQ and reported greater impairment in daily activities as measured by the Work Productivity and Activity Instrument questionnaire (P < 0.002). In multivariate analysis, after adjustment for demographic parameters, cirrhosis, and history of psychiatric disorders, having NASH was associated with lower physical HRQL scores and higher mental health–related scores (P < 0.05). DISCUSSION: Patients with NASH and advanced fibrosis have more impairment of their physical health–related scores than patients with CHC with advanced fibrosis. These data should dispel the misconception that NASH is an asymptomatic disease with little negative impact on patients’ well-being.
AB - INTRODUCTION: Although there is substantial evidence suggesting poor health-related quality of life (HRQL) in patients with chronic hepatitis C (CHC), similar data in nonalcoholic steatohepatitis (NASH) have not been fully assessed. The aim is to compare HRQL scores in patients with CHC to those with NASH. METHODS: Matched patients with advanced fibrosis (bridging fibrosis and compensated cirrhosis) due to CHC and NASH completed Short Form-36 (SF-36) questionnaire, Chronic Liver Disease Questionnaire (CLDQ), and Work Productivity and Activity Instrument questionnaire. RESULTS: We included 1,338 patients with NASH with advanced fibrosis (mean age 57.2 years, 47% men, 55% cirrhosis) and 1,338 matched patients with CHC. Patients with CHC and NASH had similar rates of employment and psychiatric disorders (P > 0.05). As expected, patients with NASH had higher body mass index (mean 33.7 vs 27.6) and more type 2 diabetes (74% vs 16%) (all P < 0.01). Patients with NASH had significantly lower HRQL scores related to physical health: Physical Functioning, Bodily Pain, General Health, Vitality, Physical Summary of SF-36, and Fatigue of CLDQ (P < 0.02). By contrast, patients with CHC had a lower Mental Health score of SF-36 and Emotional score of CLDQ and reported greater impairment in daily activities as measured by the Work Productivity and Activity Instrument questionnaire (P < 0.002). In multivariate analysis, after adjustment for demographic parameters, cirrhosis, and history of psychiatric disorders, having NASH was associated with lower physical HRQL scores and higher mental health–related scores (P < 0.05). DISCUSSION: Patients with NASH and advanced fibrosis have more impairment of their physical health–related scores than patients with CHC with advanced fibrosis. These data should dispel the misconception that NASH is an asymptomatic disease with little negative impact on patients’ well-being.
UR - http://www.scopus.com/inward/record.url?scp=85072905189&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072905189&partnerID=8YFLogxK
U2 - 10.14309/ajg.0000000000000375
DO - 10.14309/ajg.0000000000000375
M3 - Article
C2 - 31464743
AN - SCOPUS:85072905189
SN - 0002-9270
VL - 114
SP - 1636
EP - 1641
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 10
ER -